PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is an Open-Label, Crossover, Pharmacokinetic and Efficacy Bridging Study of Oral ASTX727
versus IV Decitabine in Chinese Subjects with Myelodysplastic Syndromes
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Otsuka Beijing Research Institute
Treatments:
Decitabine Decitabine and cedazuridine drug combination